P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma
Open Access
- 1 May 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (9) , 3303-3308
Abstract
Purpose: Peritoneal malignant mesothelioma is an aggressive neoplasm for which intensive therapy improves survival in a subset of patients. We hypothesized that pathologic variables would stratify patients into favorable and unfavorable survival subgroups.Keywords
This publication has 20 references indexed in Scilit:
- Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal ChemotherapyJournal of Clinical Oncology, 2003
- The Immunohistochemical Diagnosis of MesotheliomaAmerican Journal of Surgical Pathology, 2003
- Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different TypesAmerican Journal of Surgical Pathology, 2003
- Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL)Leukemia, 2002
- Diffuse malignant epithelial mesotheliomas of the peritoneum in womenCancer, 2002
- p16(MTS-1/CDKN2/INK4a) in Cancer ProgressionExperimental Cell Research, 2001
- Results of treatment of 33 patients with peritoneal mesotheliomaBritish Journal of Surgery, 2000
- A Clinicopathologic Study of Nineteen True Mesothelial Neoplasms, Other Than Adenomatoid Tumors, Multicystic Mesotheliomas, and Localized Fibrous TumorsAmerican Journal of Surgical Pathology, 1995
- Mutations associated with familial melanoma impair p16INK4 functionNature Genetics, 1995
- New strategies are needed in diffuse malignant mesotheliomaCancer, 1992